Vorasidenib becomes the first targeted therapy for grade 2 isocitrate dehydrogenase (IDH)–mutant glioma to receive FDA approval. "Today's approval of Voranigo is an enormous leap forward in cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results